UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1)

UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) is an enzyme that catalyzes the final step of the hexosamine biosynthetic pathway, synthesizing UDP-N-acetylglucosamine (UDP-GlcNAc) from UTP and N-acetylglucosamine-1-phosphate[3][4]. This nucleotide sugar is a critical substrate for both N-glycan and O-glycan biosynthesis, essential for protein glycosylation, and modulates numerous cellular processes including immune response and metabolic regulation[1][4]. UAP1 is a member of the nucleotide sugar pyrophosphorylase family, with unique domains conferring substrate specificity and catalysis dependent on a key magnesium ion and conserved lysine residues[3]. UAP1 is overexpressed in certain cancers (notably prostate and bladder cancers), supporting cell survival and tumor aggressiveness, making it a potential therapeutic target[1]. Mutations in UAP1 can cause congenital disorders of glycosylation, leading to severe developmental phenotypes[1]. While some experimental tool inhibitors (e.g., methylenebisphosphonate analogues) exist for the fungal enzyme, there are currently no approved drugs targeting mammalian UAP1 for clinical use[3][4].

Other names

UDP-N-acetylhexosamine pyrophosphorylaseSPAG2AGXAGX1AGX2Antigen XProtein-pyrophosphorylation enzymeSperm-associated antigen 2UDP-N-acetylgalactosamine pyrophosphorylaseUDP-N-acetylglucosamine diphosphorylase 1testis tissue sperm-binding protein Li 37a

Inhibition of UAP1 blocks conversion of UTP and N-acetylglucosamine-1-phosphate to UDP-GlcNAc, disrupting glycosylation and downstream cellular processes\nInhibitors target the pyrophosphorylase active site, coordinating with Mg²⁺ and essential lysine residues